Vendor Drug Program Update Change to Thiazolidinedione Clinical Prior Authorization Beginning Feb. 4, 2021, Texas Medicaid will remove Oseni criteria from the Thiazolidinediones clinical prior authorization criteria. The Oseni criteria will remain in the Dipeptidyl Peptidase-4 Inhibitors clinical prior authorization. This prior authorization is optional for use in Medicaid managed care. Other news: Revision to Kalydeco Clinical Prior Authorization Begins Dec. 28

---

You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website.

---

Stay Connected
					(en español)

Subscriber Services
Manage Preferences  |  Unsubscribe  |  Help

This email was sent to stevenmagallanes520.nims@blogger.com using govDelivery Communications Cloud on behalf of: Texas Health and Human Services Commission · 707 17th St, Suite 4000 · Denver, CO 80202